Exosomes derived from miRNA-210 overexpressing bone marrow mesenchymal stem cells protect lipopolysaccharide induced chondrocytes injury via the NF-κB pathway

He, Lei; Chen, Yuyong; Ke, Zekai; Pang, Mao; Yang, Baofeng; Feng, Feng; Wu, Zizhao; Liu, Chang; Liu, Bin; Zheng, Xiaozuo; Wu, Tao; Shu, Tao

doi:10.1016/j.gene.2020.144764

Cited by 38 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, mutations in drug targets can decrease the efficacy and toxicity of drugs. Interestingly, studies have shown that exposure to chemotherapy drugs significantly increases mutation rates in cancer cells, which may be partially attributed to the activation of pro-survival and anti-apoptotic pathways (22). Furthermore, tumor cells have a higher DNA repair rate compared with normal cells, which neutralizes any DNA damage induced by chemotherapeutic drugs and generates drug-resistant clones.…”

Section: Introductionmentioning

confidence: 99%

Exosomes: A New Pathway for Cancer Drug Resistance

Zhong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Exosomes are extracellular vesicles (EVs) that are secreted into body fluids by multiple cell types and are enriched in bioactive molecules, although their exact contents depend on the cells of origin. Studies have shown that exosomes in the tumor microenvironment affect tumor growth, metastasis and drug resistance by mediating intercellular communication and the transport of specific molecules, although their exact mechanisms of action need to be investigated further. In this review, we have summarized current knowledge on the relationship between tumor drug resistance and exosomes, and have discussed the potential applications of exosomes as diagnostic biomarkers and therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 99%

Exosomes: A New Pathway for Cancer Drug Resistance

Zhong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Chemical modification of EVs by addition of RGD peptides conjugated onto EV surfaces led the EVs to pass the blood brain barrier and target brain cells after ischemic stroke ( Tian et al, 2018 ). EVs can also be loaded with drugs by cell transfection and genetic expression of a candidate gene, or by drug encapsulation after their isolation [( Mao et al, 2019 ; He et al, 2020 ; Ou et al, 2020 ); for review, see Crivelli et al (2017) ]. MSC-EVs were extensively characterized as drug delivery platform and shown to have greater internalization capabilities than commercial liposomes ( Le Saux et al, 2020 ).…”

Section: Potential Therapeutic Use Of Mesenchymal Stem Cell-derived Ementioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation

Maumus

Rozier

Boulestreau

et al. 2020

Front. Bioeng. Biotechnol.

112

View full text Add to dashboard Cite

Extracellular vesicles (EVs), including exosomes and microvesicles, derived from mesenchymal stem/stromal cells (MSCs) exert similar effects as their parental cells, and are of interest for various therapeutic applications. EVs can act through uptake by the target cells followed by release of their cargo inside the cytoplasm, or through interaction of membrane-bound ligands with receptors expressed on target cells to stimulate downstream intracellular pathways. EV-based therapeutics may be directly used as substitutes of intact cells or after modification for targeted drug delivery. However, for the development of EV-based therapeutics, several production, isolation, and characterization requirements have to be met and the quality of the final product has to be tested before its clinical implementation. In this review, we discuss the challenges associated with the development of EV-based therapeutics and the regulatory specifications for their successful clinical translation.

show abstract

“…Moreover, Jin et al demonstrated that the exosomes secreted by miR-26a-5p-overexpressed human bone MSCs alleviated the damage of synovial fibroblasts by targeting prostaglandin-endoperoxide synthase 2 (PTGS2), thereby attenuating OA (Jin et al, 2020b ). In addition, He et al explored the protective mechanism of the exosomes from miR-210-over-expressed BMSCs (BMSCs-210-Exos) against lipopolysaccharide (LPS)-induced cartilage injury, and the results suggested that the anti-apoptotic function in chondrocytes was related to the inhibition of tumor necrosis factor receptor superfamily member 21 (Tnfrsf21) expression and the reduction of NF-κB pathway by BMSCs-210-Exos (He et al, 2020b ).…”

Section: Role Of Evs In the Treatment Of Articular Cartilage Lesions And Degenerative Joint Diseasesmentioning

confidence: 99%

Diagnostic and Therapeutic Role of Extracellular Vesicles in Articular Cartilage Lesions and Degenerative Joint Diseases

Qiao

Chen

Cao

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Two leading contributors to the global disability are cartilage lesions and degenerative joint diseases, which are characterized by the progressive cartilage destruction. Current clinical treatments often fail due to variable outcomes and an unsatisfactory long-term repair. Cell-based therapies were once considered as an effective solution because of their anti-inflammatory and immunosuppression characteristics as well as their differentiation capacity to regenerate the damaged tissue. However, stem cell-based therapies have inherent limitations, such as a high tumorigenicity risk, a low retention, and an engraftment rate, as well as strict regulatory requirements, which result in an underwhelming therapeutic effect. Therefore, the non-stem cell-based therapy has gained its popularity in recent years. Extracellular vesicles (EVs), in particular, like the paracrine factors secreted by stem cells, have been proven to play a role in mediating the biological functions of target cells, and can achieve the therapeutic effect similar to stem cells in cartilage tissue engineering. Therefore, a comprehensive review of the therapeutic role of EVs in cartilage lesions and degenerative joint diseases can be discussed both in terms of time and favorability. In this review, we summarized the physiological environment of a joint and its pathological alteration after trauma and consequent changes in EVs, which are lacking in the current literature studies. In addition, we covered the potential working mechanism of EVs in the repair of the cartilage and the joint and also discussed the potential therapeutic applications of EVs in future clinical use.

show abstract

Exosomes derived from miRNA-210 overexpressing bone marrow mesenchymal stem cells protect lipopolysaccharide induced chondrocytes injury via the NF-κB pathway

Cited by 38 publications

References 36 publications

Exosomes: A New Pathway for Cancer Drug Resistance

Exosomes: A New Pathway for Cancer Drug Resistance

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation

Diagnostic and Therapeutic Role of Extracellular Vesicles in Articular Cartilage Lesions and Degenerative Joint Diseases

Contact Info

Product

Resources

About